Chronic Lymphocytic Leukemia | Specialty

Final GENUINE Data Support Addition of Ublituximab to BTK Inhibitors in Relapsed/Refractory, High-Risk CLL

February 23rd 2021

Feburary 23, 2021 — The addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone with acceptable safety in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

Dr. Bociek on the Evolving Role of Chemoimmunotherapy in CLL

February 22nd 2021

R. Gregory Bociek, MD, discusses the evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Shadman on the Potential for CAR T-Cell Therapy in High-Risk CLL

February 20th 2021

Mazyar Shadman, MD, discusses the potential for CAR T-cell therapy in patients with high-risk chronic lymphocytic leukemia.

Dr. Shadman on the Potential Utility of LOXO-305 in CLL

February 18th 2021

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia

February 17th 2021

Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.

Chronic Lymphocytic Leukemia Treatment Considerations 

February 17th 2021

Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.

Targeted Therapies Reign in the Frontline Treatment of CLL

February 16th 2021

Jacqueline Claudia Barrientos, MD, MS, explaines how she navigates among the options available in the frontline setting for patients with CLL and highlighted ongoing research efforts of interest.

Dr. Mead on the Clinical Significance of the MURANO Trial in CLL

February 15th 2021

Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.

Dr. Shadman on Treatment Considerations in CLL

February 12th 2021

Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.

Role of Venetoclax in Chronic Lymphocytic Leukemia

February 10th 2021

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

A Look at the ECOG 1912 and iLLUMINATE Trials

February 10th 2021

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

February 8th 2021

A Look at the ELEVATE-TN and ASCEND Trials

February 3rd 2021

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.

Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.

BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.

BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm

January 27th 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL

January 26th 2021

January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.

Acalabrutinib Approved in Japan for Relapsed/Refractory CLL

January 25th 2021

January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.